Immune Checkpoint Inhibitors Have Led to Substantial Improvements in Lung Cancer but Are Still Not a ‘Cure’
Edward B. GaronBy Edward B. Garon, MD Immune checkpoint inhibitors have dramatically changed the treatment of patients with lung cancer. The degree of efficacy seen with these agents would have been nearly […] Read more
Liquid biopsy for early lung cancer detection and cancer interception
Christian Rolfo, MD, PhD, MBA, DrhcBy Christian Rolfo, MD, PhD, MBA, Dr.hc. Over the past several years, three large randomized clinical trials demonstrated that low-dose computed tomography (LDCT) screening is a valuable method for lung […] Read more
The Chen-Huang Center for EGFR-Mutant Lung Cancers Represents a ‘Concentrated and Focused Effort’ in Studying Th is Disease Subset
Posted: August 21, 2020 The Chen-Huang Center for EGFR Mutant Lung Cancers, founded at Dana-Farber Cancer Institute earlier this year, is poised to make advances in the study and treatment […] Read more
By Ben Solomon, MBBS, PhD, FRACP Posted: August 21, 2020 ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur in never smokers and […] Read more
By Joy Curzio Posted: August 21, 2020 The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), has a 2019 […] Read more
Telehealth: Bridging the Digital Divide Is Still a Work In Progress
By Sandip Pravin Patel, MD, and Martin Edelman, MD Posted: August 21, 2020 Dr. Sandip Pravin Patel Dr. Martin Edelman […] Read more
By Maria Antonia Velez, MD; Nanruoyi Zhou, BA; Brian Henick, MD; and Aaron Lisberg, MD Posted: August 21, 2020 Immune checkpoint inhibitors (CPIs) have revolutionized the treatment of metastatic NSCLC. […] Read more
By Jacek Jassem, MD, PhD, and Carolyn Dresler, MD, MPA Posted: August 21, 2020 The world is currently overwhelmed with cases of the novel virus COVID-19 and its devastating death […] Read more
Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication
By Erik MacLaren, PhD Posted: August 21, 2020 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Merck’s immune checkpoint inhibitor pembrolizumab, adding a new tissue-agnostic indication […] Read more
Bringing Telehealth to the Front Lines of Lung Cancer Care in the COVID-19 Pandemic
By Luis E. Raez, MD, FACP, FCCP Posted: August 21, 2020 Our current electronic medical records (EMR) are equipped with telehealth capability. Some of us have spent the last 2 […] Read more